BioCardia, Inc. BCDA
0.89 USD -0.02 (-1.67%)
At closeNov 5, 2026, 4:00 PM EST
0.89 0.00 0.00%
After hours · Nov 5, 4:00 PM ET
0.8401 Day range 0.91
0.77 52-week range 1.47
- YTD
- -28.80%
- 1 year
- -32.58%
News
benzinga.com BioCardia Receives FDA Acceptance For Its Pre-Submission Package For Marketing Clearance Of Its Helix Catheter For Therapeutic And Diagnostic Agent Delivery BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the FDA has accepted its…
globenewswire.com BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter SUNNYVALE, Calif., Oct. 19, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
globenewswire.com BioCardia Presents CardiAMP HF II Trial Design at Heart Failure Society of America Annual Scientific Meeting SUNNYVALE, Calif., Oct. 07, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…- benzinga.com BioCardia Resubmits Pre-Submission To FDA For Its Q-Submission Program For Approval Of Its Helix Catheter For Therapeutic, Diagnostic Agent Delivery To The Heart BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its revised…
globenewswire.com BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter SUNNYVALE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
benzinga.com BioCardia Advancing Towards Shonin Pre-Market Regulatory Submission To Japan's Pharmaceutical And Medical Device Agency In Q4; Plans To File Follow-On De Novo Pre-Submission For Helix Transendocardial Delivery Catheter System BioCardia, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update on near term…
globenewswire.com BioCardia Confirms Timing and Provides Update on FDA Helix Pre-Submission and PMDA CardiAMP HF Shonin Submission SUNNYVALE, Calif., Sept. 23, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
benzinga.com BioCardia Shares Fall 10% After Hours: Here's Why BioCardia shares fall 10% after hours after Nasdaq confirms the company regained listing compliance.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Basel Medical Group (NASDAQ:BMGL) stock moved upwards by 14.1% to $4.68 during Wednesday's after-market session. The market value of their outstanding shares is at $8.3 million. Alaunos…
globenewswire.com BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference SUNNYVALE, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Lakewood-Amedex (NASDAQ:LABT) stock rose 38.0% to $3.45 during Monday's after-market session. The company's market cap stands at $5.4 million. Alamar Biosciences (NASDAQ:ALMR) stock rose 7.4%…
globenewswire.com BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval SUNNYVALE, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
seekingalpha.com BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript BioCardia, Inc. (BCDA) Q2 2026 Earnings Call Transcript- benzinga.com BioCardia Q2 EPS $(0.13) Beats $(0.18) Estimate BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.18) by 27.78 percent. This is a 67.5 percent increase over losses of $(0.40)…
globenewswire.com BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026 SUNNYVALE, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,…
zacks.com New Strong Sell Stocks for July 28th LUNR, GLDG and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 28, 2026.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Ernexa Therapeutics (NASDAQ:ERNA) stock increased by 88.3% to $11.41 during Wednesday's pre-market session. The market value of their outstanding shares is at $7.0 million. Catheter Precision…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Exicure (NASDAQ:XCUR) stock rose 38.4% to $2.38 during Tuesday's after-market session. The market value of their outstanding shares is at $10.5 million. Catheter Precision (AMEX:VTAK) stock…
zacks.com New Strong Sell Stocks for July 14th AZ, AISP and BCDA have been added to the Zacks Rank #5 (Strong Sell) List on July 14th, 2026.
benzinga.com BioCardia CEO Issued Shareholder Letter To Provide Update; Milestone Includes Submission For Japan's Pharmaceutical and Medical Device Agency Approval Planned For End Of 2026; Driving To Enroll Confirmatory CardiAMP HF II Trial In US Dear Fellow Shareholders,Upon completion of our recent capital raise, I am providing this update on our strategy, top priorities, and business development opportunities to ensure understanding and…
globenewswire.com BioCardia Letter to Stockholders on 2026 Priorities and Strategic Opportunities SUNNYVALE, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
benzinga.com What's Going On With BioCardia Stock Tuesday? BioCardia (BCDA) stock slides after a $4.4M share dilution, but analysts spot massive upside. Check out the vital levels to watch.- benzinga.com HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $25 Price Target HC Wainwright & Co. analyst Joseph Pantginis reiterates BioCardia (NASDAQ:BCDA) with a Buy and maintains $25 price target.
benzinga.com BioCardia Sells 3,509,604 Shares At Average Price Of $1.279 On June 5; No Warrants Issued In Capital Raise Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full…
globenewswire.com BioCardia Announces $4.4 Million Financing Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full…- benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session
benzinga.com Why Is BioCardia Stock Gaining Friday? BioCardia Inc. (NASDAQ:BCDA) stock is up on Friday as the company is confirming progress toward potential market approval for its CardiAMP cell therapy.
benzinga.com Why Is BioCardia Stock Gaining Friday? BioCardia stock breaks above its 200-day moving average on huge FDA news. Can BCDA clear the $1.50 resistance? Get the technical outlook.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session - benzinga.com BioCardia Receives FDA Confirmation For Its Biologics Evaluation And Research On CardiAMP Cell Therapy System To Treat Ischemic Heart Failure Of Reduced Ejection Fraction BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced receipt of FDA minutes from its…
globenewswire.com FDA Confirms CardiAMP HF II May Support Premarket Approval of CardiAMP Cell Therapy for Ischemic HFrEF SUNNYVALE, Calif., June 05, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
benzinga.com BioCardia Announces Presentation Of Data From CardiAMP Minimally-Invasive Chronic Myocardial Ischemia Treatment Trial Demonstrating Positive Clinical Outcomes Results presented by Dr. Raval, on behalf of the CardiAMP CMI Investigators, showed that the minimally invasive CardiAMP Cell Therapy procedure was well tolerated with no treatment emergent major…
globenewswire.com BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Results Presented at EuroPCR Showed Durable Improvements in Exercise Tolerance with Reduced Angina Frequency – Positive CardiAMP CMI Trial open-label cohort results demonstrated opportunity for locally delivered cell therapy to enhance therapeutic options for patients with severely symptomatic refractory…
seekingalpha.com BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript BioCardia, Inc. (BCDA) Q1 2026 Earnings Call Transcript
benzinga.com BioCardia Q1 2026 Earnings Call: Complete Transcript 
benzinga.com BioCardia Q1 EPS $(0.21) Misses $(0.17) Estimate BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.17) by 23.53 percent. This is a 64.41 percent increase over losses of $(0.59)…
globenewswire.com BioCardia Reports First Quarter 2026 Business Highlights and Financial Results SUNNYVALE, Calif., May 15, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
benzinga.com Earnings Scheduled For May 15, 2026 
globenewswire.com BioCardia to Host Q1 2026 Financial Results and Corporate Update Conference Call on May 15, 2026 SUNNYVALE, Calif. , May 11, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [NASDAQ: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases,…- benzinga.com BioCardia Says FDA Raised No Safety Concerns, Outlines Two Clearance Pathways For Helix Catheter System BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced the outcome of its Pre-Submission…
globenewswire.com BioCardia and FDA Align on Helix Transendocardial Delivery Catheter Clearance Pathways SUNNYVALE, Calif. , May 08, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary…
benzinga.com BioCardia Files Request For FDA Meeting Related To Approval For CardiAMP System For Ischemic Chronic Heart Failure BioCardia®, Inc. (NASDAQ:BCDA), a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported submission to United States Food…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com BioCardia Q4 EPS $(0.06) Beats $(0.17) Estimate BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.17) by 64.71 percent. This is a 76 percent increase over losses of $(0.25) per…- benzinga.com Earnings Scheduled For March 24, 2026
- benzinga.com The FDA Accepts Biocardia's Pre-submission Package For The Approval Of Its Helix Transendocardial Delivery Catheter Intended For Intramyocardial Therapeutic And Diagnostic Agent Delivery BioCardia has had preliminary meetings with both FDA Center for Devices and Radiological Health (CDRH) and FDA Center for Biological Evaluation and Research (CBER) on this submission in recent weeks.…
- benzinga.com BioCardia Completes Pre-Submission To FDA Under Q-Submission Program For Approval Of Helix Transendocardial Delivery Catheter For Intramyocardial Therapeutic And Diagnostic Agent Delivery BioCardia, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its Pre-Submission to…
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
benzinga.com BioCardia Completes Third Preliminary Clinical Consultation With Japan's PMDA On CardiAMP Cell Therapy Intended For Treatment Of HFrEF BioCardia®, Inc. (NASDAQ:BCDA), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, announces it has completed a third preliminary…- benzinga.com BioCardia Q3 EPS $(0.24) Beats $(0.25) Estimate BioCardia (NASDAQ:BCDA) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.25) by 4 percent. This is a 60.66 percent increase over losses of $(0.61) per…